Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma
作者： Tim F Cloughesy , Koji Yoshimoto , Phioanh Nghiemphu , Kevin Brown , Julie Dang
DOI: 10.1371/JOURNAL.PMED.0050008
关键词: PTEN 、 PI3K/AKT/mTOR pathway 、 Population 、 Sirolimus 、 Glioma 、 TOR Serine-Threonine Kinases 、 Protein kinase B 、 Biology 、 Cancer research 、 Ribosomal protein s6 、 Immunology
摘要: … To determine if 7 d of rapamycin treatment had any antitumor activity, we assessed the proliferation rate of matched S1 and S2 samples by measuring the Ki-67 labeling index. …
elsevier.com
paperity.org
core.ac.uk 参考文章(54)
André Marette, Frédéric Tremblay, Amino Acid and Insulin Signaling via the mTOR/p70 S6 Kinase Pathway A NEGATIVE FEEDBACK MECHANISM LEADING TO INSULIN RESISTANCE IN SKELETAL MUSCLE CELLS Journal of Biological Chemistry. ,vol. 276, pp. 38052- 38060 ,(2001) , 10.1074/JBC.M106703200
Debashis Sarker, Paul Workman, Pharmacodynamic biomarkers for molecular cancer therapeutics Advances in Cancer Research. ,vol. 96, pp. 213- 268 ,(2006) , 10.1016/S0065-230X(06)96008-4
Joseph Gera, Alan Lichtenstein, Jung-hsin Hsu, Yijiang Shi, Liping Hu, Robert Bookstein, Weiqun Li, Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Research. ,vol. 62, pp. 5027- 5034 ,(2002)
Roberto Bianco, Incheol Shin, Christoph A Ritter, F Michael Yakes, Andrea Basso, Neal Rosen, Junji Tsurutani, Phillip A Dennis, Gordon B Mills, Carlos L Arteaga, Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors Oncogene. ,vol. 22, pp. 2812- 2822 ,(2003) , 10.1038/SJ.ONC.1206388
Dos D Sarbassov, Siraj M Ali, Shomit Sengupta, Joon-Ho Sheen, Peggy P Hsu, Alex F Bagley, Andrew L Markhard, David M Sabatini, None, Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Molecular Cell. ,vol. 22, pp. 159- 168 ,(2006) , 10.1016/J.MOLCEL.2006.03.029
K. Podsypanina, R. T. Lee, C. Politis, I. Hennessy, A. Crane, J. Puc, M. Neshat, H. Wang, L. Yang, J. Gibbons, P. Frost, V. Dreisbach, J. Blenis, Z. Gaciong, P. Fisher, C. Sawyers, L. Hedrick-Ellenson, R. Parsons, An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/− mice Proceedings of the National Academy of Sciences of the United States of America. ,vol. 98, pp. 10320- 10325 ,(2001) , 10.1073/PNAS.171060098
Sandrine Faivre, Guido Kroemer, Eric Raymond, Current development of mTOR inhibitors as anticancer agents Nature Reviews Drug Discovery. ,vol. 5, pp. 671- 688 ,(2006) , 10.1038/NRD2062
Philippe P. Roux, David Shahbazian, Hieu Vu, Marina K. Holz, Michael S. Cohen, Jack Taunton, Nahum Sonenberg, John Blenis, RAS/ERK Signaling Promotes Site-specific Ribosomal Protein S6 Phosphorylation via RSK and Stimulates Cap-dependent Translation Journal of Biological Chemistry. ,vol. 282, pp. 14056- 14064 ,(2007) , 10.1074/JBC.M700906200
R. Yatscoff, R. Keenan, D. LeGatt, P. Chackowsky, Blood distribution of rapamycin Clinical Biochemistry. ,vol. 26, pp. 124- ,(1993) , 10.1016/0009-9120(93)90044-7
Mary-Ann Bjornsti, Peter J. Houghton, The tor pathway: a target for cancer therapy Nature Reviews Cancer. ,vol. 4, pp. 335- 348 ,(2004) , 10.1038/NRC1362